Local Drug Delivery Systems in Periodontics

Local drug delivery systems place an antimicrobial or other therapeutic agent directly into the periodontal pocket, where a controlled-release vehicle maintains the drug above effective concentrations at the target site. The approach is used as an adjunct to mechanical instrumentation, aiming to suppress residual pathogens while avoiding the systemic exposure of oral antibiotics.

Definition

Local drug delivery in periodontics is the subgingival placement of a controlled- or sustained-release formulation that maintains therapeutic concentrations of an antimicrobial or other agent within the periodontal pocket as an adjunct to mechanical debridement.

Scope

The entry covers the rationale for site-specific delivery, the controlled-release vehicles used (fibers, gels, chips, microspheres), the principal agents, and the modest and site-limited benefit reported as an adjunct to instrumentation. It treats local delivery conceptually and does not provide product- or dose-specific instructions.

Key concepts

• Site-specific (intra-pocket) delivery
• Controlled and sustained release
• Delivery vehicles: fibers, gels, chips, microspheres
• Adjunct to subgingival instrumentation
• Reduced systemic exposure versus oral antibiotics
• Residual or non-responding pocket
• Substantivity at the target site

Mechanisms

After mechanical debridement, residual bacteria may persist in deep or anatomically complex sites. A local delivery system releases its agent over time within the pocket, keeping drug concentrations high where they are needed while limiting systemic distribution; this can further suppress the subgingival microbiota and support inflammation resolution at the treated site. Because the effect is confined to the pocket where the device is placed, the benefit is site-specific rather than mouth-wide (Goodson 1979; Tan 2020).

Clinical relevance

Local delivery is positioned as a selective adjunct for residual or non-responding sites rather than a routine addition, and understanding its modest, localised benefit supports critical appraisal of adjunctive periodontal evidence. This entry is descriptive and educational, not a recommendation or dosing guide for any agent.

Evidence & guidelines

Network meta-analysis of single-application local delivery agents reports small additional improvements in probing depth and attachment when added to nonsurgical therapy, varying by agent and vehicle (Tan 2020). Guidelines treat locally delivered antimicrobials as an optional adjunct that may be considered for specific non-responding sites rather than as a standard component of care (Sanz 2020).

History

The concept was pioneered by Goodson and colleagues in 1979, who demonstrated that tetracycline could be delivered locally into the pocket via a sustained-release device, founding the field of controlled intra-pocket chemotherapy. Subsequent decades produced a range of fibers, gels, chips, and microsphere formulations, whose adjunctive value has since been quantified in systematic and network meta-analyses (Tan 2020).

Debates

Is the adjunctive benefit clinically meaningful?

Meta-analyses show statistically detectable but small additional pocket-depth reductions from local delivery over instrumentation alone, and whether this translates into a worthwhile clinical advantage-and for which sites-remains contested.

Key figures

• J. Max Goodson
• Sigmund Socransky
• Connie Drisko

Seminal works

• goodson-1979
• tan-2020

Frequently asked questions

How does local drug delivery differ from systemic antibiotics in periodontics?

Local delivery places the agent directly into a specific pocket via a controlled-release vehicle, acting at that site with little systemic exposure, whereas systemic antibiotics are taken orally and act throughout the mouth and body. Local delivery is therefore site-specific, and systemic therapy is whole-mouth.

Does adding a local delivery agent improve nonsurgical treatment?

Meta-analyses report a small additional reduction in pocket depth at treated sites, but the effect is modest and localized. Guidelines treat it as an optional adjunct for selected non-responding sites rather than routine care; this entry is educational and not a recommendation.